Seelos' SLS-005 (Trehalose) Receives EC's Orphan Drug Designation to Treat Amyotrophic Lateral Sclerosis
Shots:
- EMA’s COMP has granted ODD to SLS-005 for the treatment of amyotrophic lateral sclerosis
- Under ODD- Seelos will get benefit from several incentives such as protocol assistance- reduced regulatory fees and market exclusivity
- Trehalose is a low molecular weight disaccharide (0.342 kDa) that crosses the BBB- stabilizes proteins and activates autophagy and has received the US FDA’s ODD in Nov’2020
Ref: PRNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com